Actively Recruiting
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
Led by Institute of Dermatology, Thailand · Updated on 2026-05-13
80
Participants Needed
2
Research Sites
29 weeks
Total Duration
On this page
Sponsors
I
Institute of Dermatology, Thailand
Lead Sponsor
M
MEDEZE Cosmeceutical Company Limited
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.
CONDITIONS
Official Title
VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants aged 9 years or older
- Diagnosed with androgenetic alopecia (Norwood-Hamilton III-V for males or Ludwig I-II for females)
- Able to read and write to complete study questionnaires
- Willing to maintain consistent hair color and hairstyle during the study
- Hair length in the non-balding (vertex) area at least 2 cm at each visit
- Able to attend all scheduled visits during the 24-week study period
You will not qualify if you...
- Unstable or uncontrolled systemic diseases affecting hair growth within 6 months prior to screening
- History of malignancy in past 5 years except treated basal or squamous cell carcinoma
- Psychiatric disorders or other conditions affecting safety or compliance
- Pregnant or breastfeeding women
- Diffuse hair thinning involving the occipital area
- Scalp diseases affecting hair growth (e.g., tinea, psoriasis, uncontrolled seborrheic dermatitis)
- History of hair transplantation or hair extensions within 6 months prior to screening
- Use of cosmetic hair loss concealment products within 2 weeks prior to screening
- Use of scalp light/laser therapy within 3 months prior to screening
- Use of supplements related to hair growth within 3 months prior to screening
- Use of hair products with active ingredients (e.g., caffeine, peptides) within 3 months prior to screening
- Hair procedures like mesotherapy or stem cell injection within 3 months prior to screening
- Known hypersensitivity to study products or ingredients
- Use of dutasteride within 12 months prior to screening
- Use of systemic cytotoxic agents
- Use of systemic glucocorticoids within 3 months prior to screening (except certain inhaled or topical corticosteroids)
- Use within 6 months prior to screening of minoxidil, finasteride, anti-androgens, prostaglandin analogs, estrogen/progesterone topicals, tamoxifen, drugs linked to hypertrichosis or hair loss
- Participation in another clinical trial within 1 month prior to screening or during this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Institute of dermatology
Bangkok, Bangkok, Thailand, 10400
Actively Recruiting
2
Institute of Dermatology
Bangkok, Thailand
Actively Recruiting
Research Team
C
Chinmanat Lekhavat, MD, PhD
CONTACT
S
Suchanaree Laitrakul, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here